Villere ST Denis J & Co. LLC Sells 33,245 Shares of OmniAb, Inc. (NASDAQ:OABI)

Villere ST Denis J & Co. LLC lessened its stake in shares of OmniAb, Inc. (NASDAQ:OABI) by 2.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,466,070 shares of the company’s stock after selling 33,245 shares during the period. Villere ST Denis J & Co. LLC owned approximately 1.04% of OmniAb worth $5,190,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Palumbo Wealth Management LLC raised its holdings in OmniAb by 12.5% during the 3rd quarter. Palumbo Wealth Management LLC now owns 24,640 shares of the company’s stock valued at $104,000 after buying an additional 2,744 shares during the period. SG Americas Securities LLC raised its holdings in OmniAb by 16.5% during the 4th quarter. SG Americas Securities LLC now owns 40,609 shares of the company’s stock valued at $144,000 after buying an additional 5,751 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in OmniAb by 64.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,727 shares of the company’s stock valued at $96,000 after buying an additional 8,909 shares during the period. Woodstock Corp raised its holdings in OmniAb by 1.2% during the 4th quarter. Woodstock Corp now owns 802,578 shares of the company’s stock valued at $2,841,000 after buying an additional 9,725 shares during the period. Finally, Choreo LLC purchased a new stake in OmniAb during the 4th quarter valued at $41,000. Hedge funds and other institutional investors own 72.08% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on OABI shares. Benchmark restated a “buy” rating and set a $8.00 price target on shares of OmniAb in a report on Thursday, November 14th. HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of OmniAb in a report on Thursday, November 14th.

OmniAb Stock Up 4.7 %

OABI stock opened at $3.81 on Friday. The business’s fifty day simple moving average is $3.51 and its two-hundred day simple moving average is $3.93. OmniAb, Inc. has a twelve month low of $3.10 and a twelve month high of $6.55. The firm has a market cap of $538.05 million, a price-to-earnings ratio of -6.15 and a beta of -0.12.

Insiders Place Their Bets

In other news, CEO Matthew W. Foehr sold 41,811 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total transaction of $135,467.64. Following the transaction, the chief executive officer now owns 3,749,639 shares in the company, valued at approximately $12,148,830.36. This trade represents a 1.10 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Charles S. Berkman sold 25,489 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $3.24, for a total value of $82,584.36. Following the transaction, the insider now owns 343,190 shares in the company, valued at approximately $1,111,935.60. This represents a 6.91 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 82,826 shares of company stock worth $268,356 over the last quarter. Company insiders own 8.60% of the company’s stock.

OmniAb Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.